Recent trials have shown that aspirin may be safely omitted while continuing dual therapy with an anticoagulant and P2Y12 receptor antagonist.25, 26 Aspirin may be resumed once the P2Y12 inhibitor is stopped, although recent data show that rivaroxaban monotherapy is safe and adequate in patients with stable CAD and atrial fibrillation.31 Monitor patients closely in the first 90 days after P2Y12 discontinuation for recurrent ischemic events.32 The gene discussed is P2RY12; the disease is atrial fibrillation.